Variant is a clinical stage orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. Our lead asset is Phase 2a ready VAR 200, hydroxypropyl beta cyclodextrin (HPβCD) for treatment of focal segmental glomerulosclerosis (FSGS).
Our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.
Our evolving product pipeline is targeted to the $100+ billion orphan drug market. Our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (HPβCD) for chronic treatment of two orphan indications, VAR 200: Focal Segmental Glomerulosclerosis (FSGS) and VAR 300: Alport Syndrome (AS). Both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids, contributing to impaired kidney function, ultimately leading to dialysis and/or kidney transplantation. HPβCD entraps and removes lipids that can cause injury to the kidneys, and it is expected to delay progression of disease and prevent the need for dialysis and/or transplantation in patients with FSGS and AS. Additional orphan indications for HPβCD are under review for near term development. Our longer-term plans include potential development of HPβCD for prevention of diabetic kidney disease (VAR 400).